Developer docs
API playgroundTry for free, no card

Search company profiles

Mission: Cure

Full company profile

uuid0022x9y

Namestring
Mission: Cure
Legal namestring
Mission: Cure
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Mission: Cure is a U.S.-registered 501(c)(3) nonprofit founded in 2017 and headquartered virtually in Providence, Rhode Island, focused exclusively on accelerating curative treatments for chronic pancreatitis. It operates as a multi-stakeholder alliance bringing together pancreatitis patients, caregivers, clinicians, academic researchers, biotechnology drug developers, and impact investors around a coordinated cure strategy. The organization delivers its mission through free patient education content (webinars, toolkits, patient stories, support groups), clinical trial navigation resources, and an advocacy program that links patients to research opportunities.

The organization's core technical contribution is the application of AI and statistical techniques to drug repurposing for chronic pancreatitis. In February 2019, Mission: Cure convened a four-month datathon with Elsevier (AI framework), the Pistoia Alliance, Cures Within Reach, and Cincinnati Children's Hospital (Dr. Bruce Aronow) that identified four existing approved drugs — Lacosamide, Dapsone, Rolipram, and Prednisolone — as potential pancreatitis treatments. Mission: Cure does not appear to operate proprietary technology infrastructure of its own; instead it leverages partner platforms and academic collaborators to advance its cure pipeline, including a December 2025 strategic collaboration with Cibus Therapeutics and Greenstone Biosciences to advance CBT-101 into clinical trials targeted for 2026.

Mission: Cure generates revenue through individual and corporate donations, foundation grants, peer-to-peer fundraising (Give Lively, Facebook Fundraisers), corporate sponsorships, and an innovative patient outcome financing model that combines venture philanthropy with impact investing to fund drug development. The organization holds a Charity Navigator Four Star Rating and Candid Platinum Transparency designation for 2025, indicating credible governance and reporting standards, although specific revenue figures are not publicly disclosed. Headcount is small (1–10 staff), and the organization runs as a lean virtual operation with a Co-Founder/CEO, VP of Translational Research, and seasonal interns.

Short descriptiontext

Mission: Cure is a 501(c)(3) nonprofit founded in 2017 that convenes patients, researchers, and biotech companies to accelerate curative treatments for chronic pancreatitis through AI-assisted drug repurposing, patient outcome financing, and clinical trial partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAlexandria, United States
HQ citystring
Alexandria
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
chronic pancreatitis research, patient advocacy nonprofit, clinical trial resources, patient outcome financing, drug repurposing programs
Industry3 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAC
Community Health, Prevention & Health Education
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Grantmaking and Giving Services8132
SIC code2 codes
  • Services-Health Services8000
  • Services-Social Services8300
Product category
Nonprofit Patient Advocacy Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Donations and Charitable Contributions
TypeGrants Donations
Description

Mission: Cure generates revenue through individual donations, corporate sponsorships, and charitable contributions from foundations. The organization is a registered 501(c)(3) nonprofit with EIN 84-3043384, making donations tax-deductible.

mission-cure.org
2Impact Investing
TypeOthers
Description

Mission: Cure utilizes patient outcome financing and impact investing models to fund drug development and research initiatives, aligning financial returns with patient health outcomes.

mission-cure.org
3Corporate Partnerships and Sponsorships
TypeOthers
Description

The organization receives support through corporate sponsorship and partnership programs where companies can support Mission: Cure's mission while gaining association with the pancreatitis community.

mission-cure.org
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Others
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Core offering1 text field

Mission: Cure is a patient advocacy nonprofit that funds drug development and provides free educational resources, webinars, support groups, and clinical trial information for chronic pancreatitis patients and caregivers. The organization also operates a patient outcome financing model that uses impact investing and venture philanthropy to fund research and drug development partnerships with biotechnology and pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 4 drug repurposing candidates identified for pancreatitis treatment through AI-based datathon
Product overview1 text field

Mission: Cure is a nonprofit organization founded in 2017 focused on curing pancreatitis through patient education, research advocacy, and innovative financing. Their offerings include a library of patient education webinars, personal story sharing platforms, clinical trial information resources, toolkits for patients and caregivers, support groups, and an innovative patient outcome financing model that uses impact investing to fund drug development. The organization serves as a hub connecting patients, caregivers, doctors, researchers, drug developers, and entrepreneurs in the pancreatitis community.

Product and service5 records
1Patient Education Webinars
CategoryPatient Education
Description

A library of free expert-led webinars covering pain management, nutrition, mental health, triglycerides, autoimmune pancreatitis, pediatric exocrine pancreatic insufficiency, and vitamin deficiencies for pancreatitis patients and caregivers.

2Pancreatitis Support Groups
CategoryPatient Support
Description

Community support resources that connect pancreatitis patients and caregivers with others affected by the disease for peer support and shared experience.

3Clinical Trials Information
CategoryClinical Trial Resources
Description

Resources that help patients find and join clinical trials for pancreatitis treatments, including a cure strategy overview and a research opportunity sharing platform.

4Pancreatitis Patient Toolkits
CategoryPatient Education
Description

Educational materials including a genetic testing toolkit, pain management resources, and nutrition guides designed for pancreatitis patients and caregivers.

5Patient Outcome Financing
CategoryResearch Financing
Description

An innovative financing model that uses impact investing and venture philanthropy to fund pancreatitis research and drug development, aligning financial returns with patient health outcomes.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Strategic collaboration to advance CBT-101, a novel therapy for chronic pancreatitis. The partnership combines drug development, stem cell, AI-based discovery, and patient advocacy to begin clinical trials in 2026 targeting an unmet medical need.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Partnering with Cibus Therapeutics and Mission: Cure to develop next-generation treatments for pancreatic and gastrointestinal diseases using stem cell and AI-based discovery platforms.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership related to TRYNGOLZA (olezarsen), the first-ever FDA-approved treatment for Familial Chylomicronemia Syndrome (FCS), a genetic cause of pancreatitis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership on FCS (Familial Chylomicronemia Syndrome) resources and New Drug Application for plozasiran targeting dangerously high triglyceride levels.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Partnership for autoimmune pancreatitis education and resources, with Katharine Provencher of IgG4ward! Foundation co-presenting webinars with Mission: Cure.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Online health community platform that launched High Triglycerides Connect with support from Ionis, providing peer support for people with high triglycerides.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Mission: Cure provided initial funding to launch the Pancreatitis Pain Research Center. Collaboration to establish the Pancreatitis Pain Research Program studying and treating specific types of pain associated with chronic pancreatitis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Collaboration on genetic testing for pancreatitis, with Dr. Mark Haupt serving as CMO of Ariel Precision Medicine and contributing to Mission: Cure's genetics resources.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Collaboration around ACG clinical guidelines for chronic pancreatitis diagnosis and management, with Mission: Cure applying these guidelines through their patient-centered care framework.

10Elsevier
Strategic tierFlagshipTypeTechnology or IntegrationAnnounced on2019-02-01
Description

Provided innovative artificial intelligence framework for the 4-month datathon aimed at identifying potential treatments for chronic pancreatitis using AI and statistical techniques.

mission-cure.org
11Pistoia Alliance
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-01
Description

Nonprofit consortium of life science companies working to lower barriers to innovation, collaborated on the datathon to identify pancreatitis drug repurposing candidates.

mission-cure.org
12Cures Within Reach
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-01
Description

Nonprofit leader in research to apply already-approved drugs to treat new diseases, collaborated on identifying and advancing drug repurposing candidates for pancreatitis.

mission-cure.org
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-02-01
Description

Academic collaboration with Dr. Bruce Aronow who developed a computable data model network for chronic pancreatitis to help determine which drugs were most likely to correct biological problems.

Peers10 records
TypeDirect peer
Description

Patient advocacy nonprofit driving research and drug development for a specific disease through community engagement and partnerships. Comparable in disease-focused, patient-led model for accelerating treatments.

TypeBroad incumbent
Description

Largest US rare disease umbrella organization with extensive grant programs, patient advocacy, and research funding. Comparable as a broad voluntary health organization with grantmaking infrastructure relevant to Mission: Cure's pancreatitis focus.

TypeDirect peer
Description

Voluntary health organization that pioneered venture philanthropy and patient outcome financing to fund drug development — the same playbook Mission: Cure is applying to pancreatitis. Highly comparable mission, financing model, and partner ecosystem.

TypeDirect peer
Description

Disease-specific nonprofit that combines patient advocacy, research funding, and biotech partnership development. Comparable in venture philanthropy-style approach to advancing therapeutics for a single disease area.

TypeDirect peer
Description

Disease-specific voluntary health organization funding research, providing patient services, and driving clinical trial enrollment. Highly comparable operating model and biotech partnership approach, applied to a different disease.

6National Pancreas Foundation
TypeDirect peer
Description

Patient advocacy and research funding nonprofit focused specifically on pancreatic diseases including pancreatitis. Directly comparable disease focus, patient community, and clinical/researcher resources.

TypeDirect peer
Description

Rare disease advocacy and policy nonprofit accelerating therapeutic development through legislative and funding initiatives. Comparable in mission alignment with Mission: Cure's rare/orphan pancreatitis focus and biotech advocacy role.

TypeDirect peer
Description

Major pancreatic disease nonprofit driving research funding, clinical trial enrollment, and patient services. Comparable in disease adjacency, patient advocacy GTM, and biotech partnership model, though focused on oncology rather than pancreatitis.

9Cures Within Reach
TypeDirect peer
Description

Nonprofit leader in drug repurposing for new diseases — a direct collaborator with Mission: Cure on the 2019 datathon. Comparable in therapeutic strategy (repositioning approved drugs) and nonprofit research funding model.

TypeBroad incumbent
Description

CZI's Rare As One Network funds and convenes rare disease patient organizations, of which Mission: Cure is a member. Comparable as a funder/convener ecosystem for rare disease nonprofits pursuing patient-led cures.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mission: Cure

Nonprofit Patient Advocacy Servicesmission-cure.org

Mission: Cure is a 501(c)(3) nonprofit founded in 2017 that convenes patients, researchers, and biotech companies to accelerate curative treatments for chronic pancreatitis through AI-assisted drug repurposing, patient outcome financing, and clinical trial partnerships.

What Mission: Cure does

Mission: Cure is a U.S.-registered 501(c)(3) nonprofit founded in 2017 and headquartered virtually in Providence, Rhode Island, focused exclusively on accelerating curative treatments for chronic pancreatitis. It operates as a multi-stakeholder alliance bringing together pancreatitis patients, caregivers, clinicians, academic researchers, biotechnology drug developers, and impact investors around a coordinated cure strategy. The organization delivers its mission through free patient education content (webinars, toolkits, patient stories, support groups), clinical trial navigation resources, and an advocacy program that links patients to research opportunities.

The organization's core technical contribution is the application of AI and statistical techniques to drug repurposing for chronic pancreatitis. In February 2019, Mission: Cure convened a four-month datathon with Elsevier (AI framework), the Pistoia Alliance, Cures Within Reach, and Cincinnati Children's Hospital (Dr. Bruce Aronow) that identified four existing approved drugs — Lacosamide, Dapsone, Rolipram, and Prednisolone — as potential pancreatitis treatments. Mission: Cure does not appear to operate proprietary technology infrastructure of its own; instead it leverages partner platforms and academic collaborators to advance its cure pipeline, including a December 2025 strategic collaboration with Cibus Therapeutics and Greenstone Biosciences to advance CBT-101 into clinical trials targeted for 2026.

Mission: Cure generates revenue through individual and corporate donations, foundation grants, peer-to-peer fundraising (Give Lively, Facebook Fundraisers), corporate sponsorships, and an innovative patient outcome financing model that combines venture philanthropy with impact investing to fund drug development. The organization holds a Charity Navigator Four Star Rating and Candid Platinum Transparency designation for 2025, indicating credible governance and reporting standards, although specific revenue figures are not publicly disclosed. Headcount is small (1–10 staff), and the organization runs as a lean virtual operation with a Co-Founder/CEO, VP of Translational Research, and seasonal interns.

Mission: Cure firmographics

Firmographics
Name
Mission: Cure
Legal name
Mission: Cure
Website
https://mission-cure.org
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Mission: Cure is a 501(c)(3) nonprofit founded in 2017 that convenes patients, researchers, and biotech companies to accelerate curative treatments for chronic pancreatitis through AI-assisted drug repurposing, patient outcome financing, and clinical trial partnerships.
Ownership category
akta.pro rank

Mission: Cure industry classification

Industry
Product category
Nonprofit Patient Advocacy Services
NAICS
Voluntary Health Organizations (813212), Grantmaking and Giving Services (8132)
SIC
Services-Health Services (8000), Services-Social Services (8300)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
SECONDARYBPAGACAC
Community Health, Prevention & Health Education

Keywords

  • Chronic pancreatitis research
  • Patient advocacy nonprofit
  • Clinical trial resources
  • Patient outcome financing
  • Drug repurposing programs

Where Mission: Cure is headquartered

Location

Headquarters

HQ city
Alexandria
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Mission: Cure business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

  1. Donations and Charitable Contributions: Mission: Cure generates revenue through individual donations, corporate sponsorships, and charitable contributions from foundations. The organization is a registered 501(c)(3) nonprofit with EIN 84-3043384, making donations tax-deductible.
  2. Impact Investing: Mission: Cure utilizes patient outcome financing and impact investing models to fund drug development and research initiatives, aligning financial returns with patient health outcomes.
  3. Corporate Partnerships and Sponsorships: The organization receives support through corporate sponsorship and partnership programs where companies can support Mission: Cure's mission while gaining association with the pancreatitis community.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Mission: Cure product offering

Product offering

Core offering

Mission: Cure is a patient advocacy nonprofit that funds drug development and provides free educational resources, webinars, support groups, and clinical trial information for chronic pancreatitis patients and caregivers. The organization also operates a patient outcome financing model that uses impact investing and venture philanthropy to fund research and drug development partnerships with biotechnology and pharmaceutical companies.

Product overview

Mission: Cure is a nonprofit organization founded in 2017 focused on curing pancreatitis through patient education, research advocacy, and innovative financing. Their offerings include a library of patient education webinars, personal story sharing platforms, clinical trial information resources, toolkits for patients and caregivers, support groups, and an innovative patient outcome financing model that uses impact investing to fund drug development. The organization serves as a hub connecting patients, caregivers, doctors, researchers, drug developers, and entrepreneurs in the pancreatitis community.

Differentiator

Problem solved

Functional benefit

Products and services

  • Patient Education Webinars A library of free expert-led webinars covering pain management, nutrition, mental health, triglycerides, autoimmune pancreatitis, pediatric exocrine pancreatic insufficiency, and vitamin deficiencies for pancreatitis patients and caregivers.
  • Pancreatitis Support Groups Community support resources that connect pancreatitis patients and caregivers with others affected by the disease for peer support and shared experience.
  • Clinical Trials Information Resources that help patients find and join clinical trials for pancreatitis treatments, including a cure strategy overview and a research opportunity sharing platform.
  • Pancreatitis Patient Toolkits Educational materials including a genetic testing toolkit, pain management resources, and nutrition guides designed for pancreatitis patients and caregivers.
  • Patient Outcome Financing An innovative financing model that uses impact investing and venture philanthropy to fund pancreatitis research and drug development, aligning financial returns with patient health outcomes.

Quantifiable outcome

  • 4 drug repurposing candidates identified for pancreatitis treatment through AI-based datathon

Companies that use Mission: Cure

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Mission: Cure technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mission: Cure partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core, minor and flagship.

  • Cibus TherapeuticscoreStrategic or Co-development Partner · 1 December 2025Strategic collaboration to advance CBT-101, a novel therapy for chronic pancreatitis. The partnership combines drug development, stem cell, AI-based discovery, and patient advocacy to begin clinical trials in 2026 targeting an unmet medical need.
  • Greenstone BiosciencescoreStrategic or Co-development Partner · 1 December 2025Partnering with Cibus Therapeutics and Mission: Cure to develop next-generation treatments for pancreatic and gastrointestinal diseases using stem cell and AI-based discovery platforms.
  • Ionis PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2025Partnership related to TRYNGOLZA (olezarsen), the first-ever FDA-approved treatment for Familial Chylomicronemia Syndrome (FCS), a genetic cause of pancreatitis.
  • Arrowhead PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2025Partnership on FCS (Familial Chylomicronemia Syndrome) resources and New Drug Application for plozasiran targeting dangerously high triglyceride levels.
  • IgG4ward! FoundationminorStrategic or Co-development Partner · 1 January 2025Partnership for autoimmune pancreatitis education and resources, with Katharine Provencher of IgG4ward! Foundation co-presenting webinars with Mission: Cure.
  • InspireminorStrategic or Co-development Partner · 1 January 2025Online health community platform that launched High Triglycerides Connect with support from Ionis, providing peer support for people with high triglycerides.
  • Johns Hopkins MedicineflagshipStrategic or Co-development Partner · 1 January 2022Mission: Cure provided initial funding to launch the Pancreatitis Pain Research Center. Collaboration to establish the Pancreatitis Pain Research Program studying and treating specific types of pain associated with chronic pancreatitis.
  • Ariel Precision MedicinecoreStrategic or Co-development Partner · 1 January 2022Collaboration on genetic testing for pancreatitis, with Dr. Mark Haupt serving as CMO of Ariel Precision Medicine and contributing to Mission: Cure's genetics resources.
  • American College of GastroenterologycoreStrategic or Co-development Partner · 1 January 2022Collaboration around ACG clinical guidelines for chronic pancreatitis diagnosis and management, with Mission: Cure applying these guidelines through their patient-centered care framework.
  • ElsevierflagshipTechnology or Integration · 1 February 2019Provided innovative artificial intelligence framework for the 4-month datathon aimed at identifying potential treatments for chronic pancreatitis using AI and statistical techniques.
  • Pistoia AlliancecoreStrategic or Co-development Partner · 1 February 2019Nonprofit consortium of life science companies working to lower barriers to innovation, collaborated on the datathon to identify pancreatitis drug repurposing candidates.
  • Cures Within ReachcoreStrategic or Co-development Partner · 1 February 2019Nonprofit leader in research to apply already-approved drugs to treat new diseases, collaborated on identifying and advancing drug repurposing candidates for pancreatitis.
  • Cincinnati Children's Hospital (Dr. Bruce Aronow)coreStrategic or Co-development Partner · 1 February 2019Academic collaboration with Dr. Bruce Aronow who developed a computable data model network for chronic pancreatitis to help determine which drugs were most likely to correct biological problems.

Scale indicators3 records

Mission: Cure competitors and assessment

Company assessment

Direct peers

  • Beyond Celiac: Patient advocacy nonprofit driving research and drug development for a specific disease through community engagement and partnerships. Comparable in disease-focused, patient-led model for accelerating treatments.
  • Cystic Fibrosis Foundation: Voluntary health organization that pioneered venture philanthropy and patient outcome financing to fund drug development — the same playbook Mission: Cure is applying to pancreatitis. Highly comparable mission, financing model, and partner ecosystem.
  • Parent Project Muscular Dystrophy: Disease-specific nonprofit that combines patient advocacy, research funding, and biotech partnership development. Comparable in venture philanthropy-style approach to advancing therapeutics for a single disease area.
  • ALS Association: Disease-specific voluntary health organization funding research, providing patient services, and driving clinical trial enrollment. Highly comparable operating model and biotech partnership approach, applied to a different disease.
  • National Pancreas Foundation: Patient advocacy and research funding nonprofit focused specifically on pancreatic diseases including pancreatitis. Directly comparable disease focus, patient community, and clinical/researcher resources.
  • EveryLife Foundation for Rare Diseases: Rare disease advocacy and policy nonprofit accelerating therapeutic development through legislative and funding initiatives. Comparable in mission alignment with Mission: Cure's rare/orphan pancreatitis focus and biotech advocacy role.
  • Pancreatic Cancer Action Network (PanCAN): Major pancreatic disease nonprofit driving research funding, clinical trial enrollment, and patient services. Comparable in disease adjacency, patient advocacy GTM, and biotech partnership model, though focused on oncology rather than pancreatitis.
  • Cures Within Reach: Nonprofit leader in drug repurposing for new diseases — a direct collaborator with Mission: Cure on the 2019 datathon. Comparable in therapeutic strategy (repositioning approved drugs) and nonprofit research funding model.

Broad incumbents

  • National Organization for Rare Disorders (NORD): Largest US rare disease umbrella organization with extensive grant programs, patient advocacy, and research funding. Comparable as a broad voluntary health organization with grantmaking infrastructure relevant to Mission: Cure's pancreatitis focus.
  • Chan Zuckerberg Initiative — Rare As One Network: CZI's Rare As One Network funds and convenes rare disease patient organizations, of which Mission: Cure is a member. Comparable as a funder/convener ecosystem for rare disease nonprofits pursuing patient-led cures.

Market position

Strengths5 records

Weaknesses5 records

Key risks6 records

Key highlights7 records

Customer concentration

Mission: Cure social profiles

Digital presence

Mission: Cure financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mission: Cure leadership team

Management profile

Number of profiles

Profiles3 records

Mission: Cure funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mission: Cure M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mission: Cure

What does Mission: Cure do?

Mission: Cure is a patient advocacy nonprofit that funds drug development and provides free educational resources, webinars, support groups, and clinical trial information for chronic pancreatitis patients and caregivers. The organization also operates a patient outcome financing model that uses impact investing and venture philanthropy to fund research and drug development partnerships with biotechnology and pharmaceutical companies.

Is Mission: Cure a public or private company?

Mission: Cure is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Mission: Cure founded?

Mission: Cure was founded in 2017. It employs 11 to 50 people.

Where is Mission: Cure based?

Mission: Cure is headquartered in Alexandria, United States, in the North America region.

How does Mission: Cure make money?

Three revenue lines are on record. Donations and Charitable Contributions are the primary driver. The others are impact Investing and corporate Partnerships and Sponsorships.

Who are Mission: Cure's main competitors?

Direct peers on record are Beyond Celiac, Cystic Fibrosis Foundation, Parent Project Muscular Dystrophy, ALS Association, National Pancreas Foundation, EveryLife Foundation for Rare Diseases, Pancreatic Cancer Action Network (PanCAN) and Cures Within Reach. Broad incumbents are National Organization for Rare Disorders (NORD) and Chan Zuckerberg Initiative — Rare As One Network.

Does Mission: Cure have an API?

No public API is recorded for Mission: Cure.

What industry is Mission: Cure in?

Mission: Cure's product category is Nonprofit Patient Advocacy Services. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 813212 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals